Novo Nordisk's Lotte Bjerre Knudsen says her determination is a key part of the success, but she also stays humble.

This article reviews the published evidence over two decades of use of the NovoPen ® family of injection devices in diabetes management. A search for NovoPen ® publications from 1985 onwards was ...

UBS analyst Jo Walton maintained a Hold rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK1,100.00. The ...

Sol-Millennium® Medical Group, a leading manufacturer of medical devices, has launched an innovative needle-free injection ...

Tirzepatide Shows Powerful Diabetes-Prevention Effect in Three-Year Trial Nov. 26, 2024 — Tirzepatide, a new injectable weight-loss drug, reduced the risk of diabetes in patients with obesity ...

Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ($1.20 billion) in a new facility in Odense, Denmark, for the ...

Including the acquisition and expansion of the manufacturing facility, Eli Lilly will be investing $4bn in the site. After ...

Tirzepatide, a weight loss drug, shows promise in preventing diabetes by improving insulin sensitivity and aiding in weight ...

Tirzepatide, a new injectable weight-loss drug with the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period ...

Drugmaker Eli Lilly plans to invest $3 billion to expand a manufacturing facility in the Kenosha County, Wis., to meet ...